- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer's Disease
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Condition Directory
Alzheimer's Disease clinical trials
Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 14, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
707
Shown on this page
12
Current sort
Recently updated
Condition scope
Alzheimer's Disease
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Alzheimer's Disease studies are organized in the registry
The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 325–336 of 707 matching trials for Alzheimer's Disease.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease
- Interventions
- Donanemab, Aducanumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 31
- States / cities
- Fullerton, California • Irvine, California • Sherman Oaks, California + 27 more
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
- Interventions
- Florbetapir, Flortaucipir
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,182 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Insulin (Humulin® R U-100), Placebo
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Irvine, California • New Haven, Connecticut + 18 more
- Conditions
- Alzheimer Disease
- Interventions
- DBS-f On, DBS Off
- Device
- Lead sponsor
- Functional Neuromodulation Ltd
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • Stanford, California + 10 more
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- Donepezil, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Long Beach, California • Hallandale, Florida • Lady Lake, Florida + 5 more
- Conditions
- Primary Progressive Aphasia, Alzheimer Disease, Dementia
- Interventions
- Florbetapir F 18, Positron Emission Tomography
- Drug · Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Alzheimer Disease
- Interventions
- LY3002813, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 3 more
- Conditions
- Alzheimer Disease
- Interventions
- LY3002813-IV, LY3002813-SC, Placebo-IV
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 4
- States / cities
- Long Beach, California • Orlando, Florida • Atlanta, Georgia + 1 more
- Conditions
- Aging, Cognitive Ability, General
- Interventions
- Moderate-aerobic walking, Positron Emission Tomography (PET) scan, Healthy living education, Physical activity monitor
- Behavioral · Radiation · Device
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alzheimer Disease
- Interventions
- GENUS device (Active Settings), GENUS device (Sham Settings)
- Device
- Lead sponsor
- Massachusetts Institute of Technology
- Other
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Alzheimer's Disease
- Interventions
- Semorinemab, Placebo, [18F]GTP1
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 31
- States / cities
- Garden Grove, California • Los Alamitos, California • Palo Alto, California + 28 more
About this Alzheimer's Disease clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.